The Court of Appeals for the Federal Circuit upheld a district court finding of invalidity in the patent litigation case of Novozymes A/S v Dupont Nutrition Biosciences.  The Federal Circuit held that the claims of the Novozymes patent did not meet the written description requirement of 35 U.S.C Sec 112, Paragraph 1 and affirmed the lower courts finding of patent invalidity.  The Federal Court found that the disclosure upon which the Novozymes patent relied provided only general guidance listing several variables, when combined, that might lead to a useful result, but did not particularly point out the claimed invention.  The opinion can be found here  Novozymes v Dupont